Michigan Biosciences Industry Association Logo

Advocacy

Stay informed on advocacy efforts driving growth and innovation in the bio-industry. This category features updates, initiatives, and insights focused on promoting policies and actions that support our thriving community.

Advocacy Advocacy : Federal Advocacy Advocacy : State Advocacy Association Updates BioConnections® Jobs Event Event : Industry Event Event : MichBio Advocacy Events Event : MichBio Networking Event Event : MichBio Signature Event Event : MichBio Webinar Event : Partner Event Member Feature News News : Industry News News : Member News News : MichBio News/Statement News : Michigan News
Congress Enacts BIOSECURE Act: What it Means for the Life Sciences Sector
Posted In: Federal Advocacy,
Date posted Dec 22

In late December 2025, Congress completed action on the FY 2026 National Defense Authorization Act (NDAA)and with it, the...

Read Post
Federal INVEST Act Advances: What it Means for Life Sciences Innovation
Posted In: Federal Advocacy,
Date posted Dec 22

Access to capital remains one of the most persistent challenges facing early-stage life sciences companies. On December 11, the U.S. House of...

Read Post
Modernizing U.S. Scientific Enterprise: Why the NSCEB’s New Vision Demands Action
Posted In: Federal Advocacy,
Date posted Dec 8

America stands at a pivotal moment in biotechnology and scientific innovation. The National Security Commission on Emerging Biotechnology...

Read Post
A Tariff Truce with a Price Tag
Posted In: Federal Advocacy,
Date posted Dec 8

On December 1, 2025, Washington and London announced an “agreement in principle” that does two big things at once: it shields...

Read Post
New Federal R&D Opportunity: ARPA-H Launches  BioStabilization Systems (BoSS) 
Posted In: Federal Advocacy,
Date posted Dec 8

The Advanced Research Projects Agency for Health (ARPA-H) – Health & Human Service (HHS)’s “high-risk,...

Read Post
Give Kids a Chance: How Congress Moved to Restart Pediatric Drug R&D Incentives
Posted In: Federal Advocacy,
Date posted Dec 8

After the FDA’s Rare Pediatric Disease (RPD) Priority Review Voucher (PRV) authority lapsed at the end of 2024, patient groups and drug...

Read Post
PBM Reform Back in Play: Senate Reintroduces Bipartisan Transparency Package
Posted In: Federal Advocacy,
Date posted Dec 8

A major bipartisan push to overhaul pharmacy benefit managers (PBMs) is back on the Senate agenda. On Dec. 4, Senate Finance Committee...

Read Post
A Response for Drug Pricing Reform - Addressing Insurance Cost Drivers
Posted In: State Advocacy,
Date posted Nov 2

In a recent Detroit Free Press op-ed, MichBio CEO, Stephen Rapundalo, responded to an article by the CEO of Blue Cross Blue Shield of Michigan...

Read Post
Michigan House Advances HB 4254 - MichBio Raises Concerns Over Research & Economic Impacts
Posted In: State Advocacy,
Date posted Nov 2

On October 30, 2025, the Michigan House Regulatory Reform Committee voted 13-0-2 to discharge House Bill 4254. The bill, introduced by Rep....

Read Post
Senate Advances Revised BIOSECURE Act — What it Means for Biotech and Biopharma
Posted In: Federal Advocacy,
Date posted Oct 17

On October 9, 2025, the U.S. Senate took a major step toward embedding a retooled BIOSECURE Act into national policy by approving it as an...

Read Post
Proposed Section 232 Investigation on Med Device Imports Could Undermine U.S., MI's Medtech Strength
Posted In: Federal Advocacy,
Date posted Oct 17

The U.S. Department of Commerce’s decision to launch a Section 232 investigation into imports of medical devices and related equipment has...

Read Post
Parsing A New Drug Pricing Deal and What It Means for Innovation 
Posted In: Federal Advocacy,
Date posted Oct 2

The September 30, 2025, announcement that Pfizer will cut prices on selected drugs (particularly for Medicaid and uninsured populations), tied...

Read Post